Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs
Kyle LaHucik / endpoints - In its third acquisition of 2026, Gilead is spending $3.15 billion upfront to snag a next-generation antibody-drug conjugate platform from German startup Tubulis. The California biopharma could pay out another $1.85 billion down the road ...
AI Summary: Gilead Sciences struck a multibillion-dollar acquisition to add Tubulis and bolster its oncology pipeline, buying into antibody-drug conjugate technology. The deal signals Gilead’s strategic pivot to expand beyond infectious disease into cancer therapeutics, accelerating access to novel modalities and reshaping competitive dynamics in biopharma.
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio
oncodaily - Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics, marking a strategic expansion into rare disease treatments and strengthening its late-stage pipeline. The deal signals continued consolidation […]
AI Summary: Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, picking up Soleno’s Prader‑Willi treatment candidate and bolstering its rare‑disease portfolio. The purchase folds Soleno’s clinical assets and research teams into Neurocrine, positioning the buyer to commercialize a potential high‑value therapy while shoring up long‑term pipeline growth.
Anthropic acquires stealth AI startup Coefficient Bio in $400M deal: reports
fiercehealthcare - AI powerhouse Anthropic is continuing its push into the healthcare arena with the acquisition of previously stealth AI startup Coefficient Bio in a $400 million stock deal, according to reporting from The Information and Eric Newcomer.
AI Summary: Anthropic has acquired stealth biotech Coefficient Bio in a reported $400 million deal, signaling a major push by an AI developer into drug discovery. The acquisition folds computational prowess into wet‑lab capabilities, reshaping who might lead future therapeutic discovery and prompting competitors to wonder if they missed the memo.
CHS sells 180-bed hospital for $459M: 6 things to know
Alan Condon / beckershospitalreview - Franklin, Tenn.-based Community Health Systems on April 1 sold Crestwood Medical Center — a 180-bed hospital in Huntsville, Ala. — to Huntsville Hospital Health System for $459 million. Six things to know: 1. The deal includes all of the assets tied to th…
AI Summary: Community Health Systems has finalized the sale of a 180‑bed Alabama hospital for $459 million, concluding a transaction that reshuffles local care ownership and may prompt operational changes. The closing marks a notable consolidation step in regional hospital markets and raises questions about continuity and access as the new owner assumes control.
Biogen to acquire Apellis for $5.6B
Elizabeth Cairns / endpoints - Biogen has made a $5.6 billion deal to acquire Apellis Pharmaceuticals, the companies announced Tuesday. The deal will allow Biogen to get hold of the kidney disease drug Empaveli and the eye disease therapy Syfovre ...
AI Summary: Biogen agreed to acquire Apellis Pharmaceuticals for $5.6 billion, a deal pitched as a strategic move to broaden Biogen’s pipeline and bolster its biopharma foothold. Analysts and company spokespeople framed the purchase as value‑accretive, even as skeptics question integration risks and the price tag in a cautious market.
Eli Lilly’s Neuro Prospects Expand to Sleep Science With $6.3B Centessa Acquisition
Frank Vinluan / medcitynews - Centessa Pharmaceuticals’ cleminorexton is part of the orexin agonist drug class, which could introduce a new approach to the treatment of narcolepsy and other sleep disorders. Acquiring Centessa brings Eli Lilly into a group of clinical-stage orexin agon…
AI Summary: Eli Lilly announced a $6.3 billion acquisition of Centessa to secure a promising narcolepsy/sleep-disorder candidate and expand its neuroscience portfolio. The deal fast-tracks Lilly into sleep science, buying late-stage assets rather than relying on in-house miracles — a tidy shortcut to diversifying its neurotherapeutics pipeline.
“Me engañaron”: agentes encadenan a un padre que había ido al ICE a reunirse con sus hijos
Claudia Boyd-Barrett and Renuka Rayasam and Amanda Seitz / kffhealthnews - Se supone que la agencia que cuida a niños que llegan solos al país deben reunirlos pronto con sus familias o cuidadores. Pero cada vez más los usan como “carnada” para arrestar a los padres.
AI Summary: Gilead struck a deal to acquire Ouro Medicines for roughly $1.68–1.7 billion, securing an immune‑modulating autoimmune program intended to reset pathological immune responses. The transaction combines upfront cash and potential milestones, expanding Gilead’s pipeline and signaling continued industry appetite for bolt‑on buys to chase novel therapeutics.
Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug
Frank Vinluan / medcitynews - Merck has been acquiring assets that could help make up for the coming revenue decline as its top product, the cancer drug Keytruda, drops off the patent cliff. Terns Pharmaceuticals’ lead product candidate, in development for treating a type of leukemia,…
AI Summary: Merck announced a definitive deal to acquire Terns Pharmaceuticals for about $6.7 billion, gaining a promising leukemia drug candidate and bolstering its oncology pipeline. The transaction aims to combine Merck’s late‑stage development and commercialization capabilities with Terns’ targeted therapy assets to compete in hematologic malignancies.
Cencora acquiring EyeSouth Partners' retina business for $1.1B
fiercehealthcare - EyeSouth Partners' retina specialists will join Cencora's Retina Consultants of America, a management services organization that already boasts the country's largest network of retina centers.
AI Summary: Cencora has agreed to acquire EyeSouth Partners’ retina business for roughly $1.1 billion, strengthening its position in specialty ophthalmology services. The deal transfers a network of retinal care assets and aims to integrate retina-focused clinical operations and distribution under Cencora’s broader eye‑care strategy.
Justice Department sues NewYork-Presbyterian in second hospital antitrust case this year
Sydney Halleman / healthcaredive - Federal regulators accused the health system of using its market power to force insurers into “all-or-nothing” contracts. The Justice Department filed a similar lawsuit against OhioHealth last month.
AI Summary: The Justice Department filed suit alleging NewYork‑Presbyterian engaged in unfair contracting and anticompetitive practices that harmed hospitals, physicians, and patients by restricting competition and raising prices. The complaint signals intensified federal scrutiny of hospital consolidation and contractual arrangements that may lock out rivals and drive up healthcare costs.
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Ayisha Sharma / endpoints - Novartis has budgeted $2 billion upfront to buy a more selective PI3Kα inhibitor for breast cancer. The Swiss pharma already has Piqray with a similar target, but drugmakers are now entering the next-generation era as ...
AI Summary: Novartis agreed to pay $2 billion upfront to acquire Synnovation’s mutant‑selective PI3Kα inhibitor, a bet to revive and strengthen PI3K‑targeting combination strategies in breast cancer. The deal swaps in external innovation for internal development speed, shoring up the company’s oncology pipeline while quietly admitting buying is sometimes faster than building.
Why Providence Wants to Sell Its Health Plan
Katie Adams / medcitynews - Providence announced its intent to sell its health plan, exiting the “payvider” model as rising costs and operational complexity weigh on smaller regional insurers. The move reflects a broader trend of health systems refocusing on core care delivery and e…
AI Summary: Providence Healthcare is actively weighing the sale of its health insurance arm as mounting fiscal pressures force leaders to consider dramatic options. The move would reshape the system’s payer-provider footprint, potentially easing balance‑sheet strain while unnerving patients, employers and regulators who’ll suddenly have a stake in the decision.
Sutter, Allina Health Combine to Form $26B Health System
Katie Adams / medcitynews - Sutter Health is acquiring Allina Health in a deal that would create a $26 billion nonprofit health system spanning California, Minnesota and Wisconsin. The deal reflects a broader wave of hospital consolidation as providers pursue scale to manage rising …
AI Summary: Sutter Health and Allina Health have agreed to combine in a transaction that would create a $26 billion nonprofit system spanning California and Minnesota, forming a 39‑hospital network. The deal aims to consolidate operations and expand market reach, subject to definitive agreements and regulatory approvals, promising scale-driven efficiencies — and inevitably, some rebranded parking lots.
- Close watch: finances, approvals and expected closing timeline (2)
- On the ground: Sutter and Allina agree to $26B merger (3)
- Other developments: regional hospital expansions and financing moves (2)
- Trend watch: consolidation reshaping hospital markets nationwide (2)
- All Other Stories
Close watch: finances, approvals and expected closing timeline
On the ground: Sutter and Allina agree to $26B merger
Other developments: regional hospital expansions and financing moves
Trend watch: consolidation reshaping hospital markets nationwide
All Other Stories
Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision
Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…
AI Summary: GSK has licensed its investigational drug linerixibat to Alfasigma for $300 million upfront, transferring global rights as the therapy nears regulatory decisions for cholestatic liver itch. The deal accelerates Alfasigma’s rare-disease ambitions while allowing GSK to reposition its pipeline — a tidy corporate shuffle with real implications for patients with debilitating pruritus.
Universal Health Services buys Talkspace for $835M
Ngai Yeung / endpoints - Universal Health Services, which operates hospitals and mental healthcare facilities, is acquiring Talkspace for $835 million in an area closely watched for consolidation, as virtual mental health companies grapple with falling valuations despite high dem…
AI Summary: Universal Health Services agreed to acquire Talkspace for roughly $835 million to bulk up virtual behavioral‑health capabilities and outpatient telehealth services. The deal aims to expand UHS’s behavioral care footprint and diversify revenue streams, subject to customary closing conditions and regulatory review — because nothing says mental‑health innovation like a corporate merger.
MUSC Health acquires South Carolina's largest multispecialty practice for $111M
fiercehealthcare - The deal, effective March 3, includes 126 physicians and advanced practitioners, expanding the academic system's primary care capacity.
AI Summary: MUSC Health completed a $111 million acquisition of a major South Carolina multispecialty practice, expanding its primary care and outpatient capacity. The deal consolidates regional services under the academic system’s umbrella, promising integrated care and scale efficiencies — and yes, another hospital system just got a bit larger.
Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma
Frank Vinluan / medcitynews - Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in chi…
AI Summary: Servier is buying Day One Biopharmaceuticals for about $2.5 billion to bolster its rare oncology portfolio, gaining access to promising targeted therapies. The deal expands Servier’s presence in specialty cancer medicines and aligns with its strategic push into rare tumors, with integration and regulatory steps expected to follow.
Novartis closes Avidity deal as rare heart disease spinout launches
Lei Lei Wu / endpoints - Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies. The spinout will take on Avidity’s early-stage programs for genetic cardiomyopathies — heart muscle diseases ...
AI Summary: Novartis completed its Avidity Biosciences transaction and backed the launch of Atrium Therapeutics, a newly funded spinout focused on RNA therapies for rare cardiac conditions. Atrium inherits delivery platforms and early programs with substantial capital, as Novartis reshuffles assets to accelerate its RNA strategy — because apparently doubling down on hot modalities never gets old.
Gilead to acquire cell therapy manufacturer for $7.8B
Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…
AI Summary: Gilead Sciences agreed to acquire Arcellx for $7.8 billion to secure manufacturing and commercialization of a leading multiple myeloma CAR‑T candidate. The deal folds Arcellx’s anito‑cel program into Gilead’s oncology portfolio, accelerating regulatory filings and scale‑up plans — because buying your way into cutting‑edge cell therapy apparently never goes out of style.
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Kyle LaHucik / endpoints - Novartis will pay $100 million upfront to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines. The move allows the Swiss pharma giant to delve ...
AI Summary: Novartis has committed $100 million upfront to partner with Unnatural Products, acquiring access to a macrocyclic peptide platform designed to reach challenging protein targets. The deal accelerates Novartis’ efforts to expand into next‑generation peptide therapeutics and bolsters its early R&D pipeline with technology aimed at previously “undruggable” targets.